BostonGene Information

BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. BostonGene has established unrivaled credibility across oncology and immunology through a collaborative ecosystem of deep academic partnerships with MD Anderson Cancer Center, Memorial Sloan Kettering, Dana Farber Cancer Institute, the Mayo Clinic, and other leading cancer institutions across the globe. These are complemented by strategic business partnerships with AstraZeneca, Johnson & Johnson, Takeda, Ottimo Pharma, and other global pharma and biotech leaders leveraging BostonGene’s platform to drive precision medicine. Its work is reflected in more than 200 publications in top peer-reviewed journals, including Nature, Cancer Cell, and Cancer Discovery. The company's industry-leading innovation has been recognized with awards such as Frost & Sullivan’s 2025 Global Technology Innovation Leadership Award in AI-driven Precision Oncology Solutions, as well as BioTech Breakthrough’s 2025 Overall Immunology Company of the Year and 2025 AI-based Drug Discovery Solution of the Year.